Physician profile
Thomas M Snodell
NPI 1952307431
$2,678.08
in general payments reported to CMS, 2019-2025
31 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $14.83 · 2021: $61.23 · 2022: $769 · 2023: $686 · 2024: $635 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $452.52 | 2022-2025 | Jardiance, Emgality, Zepbound |
| Abbott Laboratories | $292.75 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $289.28 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $245.59 | 2022-2025 | |
| Abbvie INC. | $166.39 | 2022-2025 | Ubrelvy, Synthroid |
| Amarin Pharma, INC. | $133.58 | 2019 | |
| Daiichi Sankyo INC. | $118.94 | 2021-2023 | Injectafer |
| Teva Pharmaceuticals USA, INC. | $109.24 | 2022-2025 | Ajovy, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $102.02 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $94.88 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $67.87 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.87 | 2022 | |
| Amgen INC. | $48.06 | 2022-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $43.87 | 2023-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $43.55 | 2023-2024 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.99 | 2023-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $42.11 | 2022-2023 | |
| Boston Scientific Corporation | $41.06 | 2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.77 | 2022-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.36 | 2022-2024 | Jardiance |
| Corium, LLC | $34.42 | 2022-2023 | Azstarys |
| Sumitomo Pharma America, INC. | $28.56 | 2023 | Gemtesa |
| Dexcom, INC. | $19.76 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $19.08 | 2023 | Eliquis |
| Sanofi Pasteur INC. | $18.51 | 2023 | |
| Impel Pharmaceuticals INC. | $18.47 | 2023 | Trudhesa |
| Hologic Sales and Service, LLC | $18.24 | 2024 | Thinprep 2000 Processor, Aptima |
| Merck Sharp & Dohme LLC | $16.23 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Nevro Corp. | $14.83 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.42 | 2022 | |
| Endogastric Solutions, INC | $8.86 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Snodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.